Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2

Drugs

Volumn 62, Issue 1, 2002, Pages 209-243

  McKeage, Kate ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Metastatic breast cancer; Monoclonal antibody; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GAMMA INTERFERON; PACLITAXEL; TRASTUZUMAB;

ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC REACTION; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOLERABILITY; GENE OVEREXPRESSION; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOGENICITY; LUNG DISEASE; MULTICENTER STUDY; ONCOGENE NEU; PHARMACODYNAMICS; QUALITY OF LIFE; REVIEW;

EID: 0036179603     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262010-00008     Document Type: Review

References (84)

1. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years
2. Treatment of breast cancer
3. Biological therapy of breast cancer
4. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen
5. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer
6. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
7. HER2 causes transformation and tumorigenesis of NIH 3T3 cells
8. Trastuzumab
9. HER2 antibody for human cancer therapy
10. From the molecule to the clinic - Inhibiting HER2 to treat breast cancer
11. Pharmacology and therapeutic use of trastuzumab in breast cancer
12. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells
13. Recombinant humanized anti-HER2 antibody (Herceptin®) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
14. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
15. Models to assess combination therapy interactions: Optimal timing of anti-HER-2 antibody and doxorubicin in breast cancer
16. Increased levels of circulating HER2 ECD in response to anti-HER2 antibody therapy
17. First-line herceptin® monotherapy in metastatic breast cancer
18. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer
19. Antitumor activity of Herceptin® in combination with STEALTH® liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model
20. HER2 monoclonal antibody and cytokines
21. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER2-neu antibody
22. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2
23. CP461 induces apoptosis and growth inhibition of breast cancer cells independent of HER2/neu receptor expression
24. Cooperative inhibitory effect of ZD1839 ('Iressa') in combination with trastuzumab on human breast cancer cell growth
25. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
26. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
27. Pharmacokinetics (PK) and safety of trastuzumab (Herceptin®) when administered every three weeks to women with metastatic breast cancer
28. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
29. Herceptin® (trastuzumab) in cerebrospinal fluid
30. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
31. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer
32. A phase II trial of weekly docetaxel (D) and Herceptin (H) as first- or second-line treatment in HER2 over-expressing metastatic breast cancer
33. Phase II trial of Herceptin induction followed by combination therapy with paclitaxel and carboptatin: A Minnie Pearl Research Network trial
34. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer
35. Results of two open label multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as therapy for advanced breast cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogene
36. Weekly administration of paclitaxel, as first line chemotherapy, and Herceptin (transtuzumab) in advanced breast cancer
37. HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: A pilot study
38. Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC)
39. Taxotere, cisplatin and herceptin (TCH) in first-line HER2 positive metastatic breast cancer (MBC) patients, a phase II pilot study by the breast cancer international research group (BCIRG 101)
40. A phase II multicenter trial of weekly herceptin with navelbine in chemonaive patients with her2 positive metastatic breast cancer
41. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
42. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
43. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
44. Survival benefit of trastuzumab (Herceptin) and chemotherapy in older (age>60) patients
45. Herceptin (H) and Taxol (T) in the treatment of women with HER-2/neu overexpressing metastatic breast cancer (MBC): Prospective study
46. Herceptin and Taxol combination for metastatic breast cancer in women with HER-2/neu overexpression
47. Addition of herceptin to paclitaxel for Her2 over-expressing advanced breast cancer. Best results in skin metastasis
48. Trastuzumab (Herceptin) combined with weekly paclitaxel in the treatment of metastatic breast cancer: A phase II study
49. Efficacy and safety of three weekly herceptin with paclitaxel in women with Her2-positive metastatic breast cancer: Preliminary results of a phase II trial
50. Weekly (W) Herceptinr (H, Traztuximab) and one hour Taxol (T, paclitaxel) infusion (WHT) regimen for human epidermal growth factor receptor-2 (HER2) overexpressed (+) metastatic breast cancer (MBC)
51. Phase II study of weekly docetaxel (Taxotere; txt) and trastuzumab (Herceptin; H) for patients with HER-2 overexpressing (HER2+) metastatic breast cancer (MBC)
52. A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2
53. Treatment of HER2 overexpressing metastatic breast cancer with trastuzumab (Herceptin®) and chemotherapy
54. Preoperative trastuzumab (T) and paclitaxel (P) for HER2-overexpressing (HER2+) stage II/III breast cancer
55. Safety and efficacy of 4AC followed by paclitaxel plus trastuzumab in high risk breast cancer patients
56. Primary therapy with Herceptin, Taxotere and Cisplatin in locally advanced and inflammatory breast cancer
57. Can HER2 status predict response to cancer therapy?
58. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
59. Initial report of the HER2000 study: A multinational study of HER2 status of breast cancer using immunohistochemistry (IHC; Herceptest)
60. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH)
61. Fluorescence in situ hybridization (FISH) may accurately select patients likely to benefit from herceptin monotherapy
62. Loss of HER-2 overexpression during Herceptin®-therapy in metastatic breast cancer
63. Effects of treatment with Her2mab (trastuzumab/Herceptin) plus chemotherapy (H+C) versus chemotherapy alone (C) on health-related quality of life (HRQL) in women with HER-2/neu-overexpressing metastatic breast cancer
64. Health related quality of life (HRQL) of patients treated with first-line, single agent, trastuzumab (Herceptin) for metastatic Her-2 overexpressing breast cancer (MBC)
65. Health related quality of life (HRQL) of patients with HER-2 overexpressing, metastatic breast cancer (MBC) treated with Herceptin (trastuzumab) as a single agent
66. Cutaneous photosensitivity associated with abberations in the heme biosynthetic pathway induced by taxanes (T) and trastuzumab (H): A report of 3 cases of metastatic breast cancer
67. Bleeding risk with trastuzumab (Herceptin) treatment
68. Trastuzumab and breast cancer
69. Effect of cardiac dysfunction on treatment outcome in the herceptin pivotal trial
70. Cardiovascular adverse effects of trastuzumab in patients with stage IV breast cancer
71. Cardiac safety and efficacy of TLC D99 (D99) and trastuzumab in patients with advanced breast cancer
72. Cardiac safety of herceptin® in combination with epirubicin plus cyclophosphamide: Interim results of a phase II study in patients with metastatic breast cancer
73. Cardiac safety and antitumor activity of doxorubicin and taxol followed by weekly taxol (AT & T) when herceptin is initiated with AT or with T alone in women with HER2-positive advanced breast cancer
74. Rapid desensitization and rush immunotherapy to trastuzumab (Herceptin)
75. HER2 and trastuzumab in breast cancer
76. Developments in chemotherapy of breast cancer
77. Relationship of estrogen receptor (ER) status to clinical benefit in clinical trials of herceptin
78. Experts debate value of HER2 testing methods
79. Herceptin in the adjuvant setting: Phase III trials begin